Telix Q3 Revenue Up 19% to $245M, Reaffirms $1B+ Full-Year Outlook
TLX sits 78% above its 52-week low of $6.28.
Summary
Telix posted Q3 2026 group revenue of US$245M, up 19% year-over-year, with Precision Medicine sales of US$201M climbing 30% on strong Gozellix and Illuccix demand. The sequential picture is flatter — group revenue slipped 1% from Q2's US$247M and TMS fell 6% YoY to US$44M — but management flagged a strong September exit rate supporting confidence in over 25% Precision Medicine growth for the year. Full-year guidance was reaffirmed at US$950M-$970M revenue plus US$40M other income, tracking the upper end, while R&D spend guidance narrowed to US$240M-$260M. This follows the September 21 announcement of the US$1.65B ITM merger, which remains subject to shareholder approval at a December 1, 2026 general meeting. Pixclara's September FDA approval and first commercial doses add a new revenue line, and the Zircaix BLA resubmission is planned in the near term after the corrected CRL.
At the time of this announcement, TLX was trading at $11.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $6.28 to $13.11. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.